Tag Archives: REPLAY

Business, Finance, Occupation & Industry

Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter 2013 Financial Resu

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter 2013 Financial Results on May 7, 2013

BOTHELL, Wash.–(BUSINESS WIRE)– Seattle Genetics, Inc. (NAS: SGEN) announced today that it will report its first quarter 2013 financial results on Tuesday, May 7, 2013, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows:

LIVE access on Tuesday, May 7, 2013
1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time

REPLAY access

  • Telephone replay will be available beginning at approximately 3:30 p.m. PT on Tuesday, May 7, 2013 through 5:00 p.m. PT on Thursday, May 9, 2013 by calling 800-406-7325 (domestic) or 303-590-3030 (international); conference ID 4614604
  • Webcast replay will be available on the Seattle Genetics website at http://www.seattlegenetics.com/ in the Investors and News section

About Seattle Genetics

Seattle Genetics is a biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer. The company’s lead program, ADCETRIS® (brentuximab vedotin), received accelerated approval from the U.S. Food and Drug Administration in August 2011 and approval with conditions from Health Canada in February 2013 for two indications. In addition, under a collaboration with Millennium: The Takeda Oncology Company, ADCETRIS received conditional marketing authorization from the European Commission in October 2012. Seattle Genetics also has four other clinical-stage ADC programs: SGN-75, ASG-5ME, ASG-22ME and SGN-CD19A. Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including Abbott, Agensys (an affiliate of Astellas), Bayer, Celldex Therapeutics, Daiichi Sankyo, Genentech, GlaxoSmithKline, Millennium, Pfizer and Progenics, as well as ADC co-development agreements with Agensys and Genmab. More information can be found at www.seattlegenetics.com.

From: http://www.dailyfinance.com/2013/04/18/seattle-genetics-to-host-conference-call-and-webca/

Business, Finance, Occupation & Industry

EMCOR Group, Inc. First Quarter Conference Call to Be Broadcast over the Internet

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

EMCOR Group, Inc. First Quarter Conference Call to Be Broadcast over the Internet

NORWALK, Conn.–(BUSINESS WIRE)– EMCOR Group, Inc. (NYS: EME) intends to release its first quarter 2013 results for the period ended March 31, 2013 on Thursday, April 25, 2013. In conjunction with this release, EMCOR Group will host a conference call, which will be simultaneously broadcast live over the Internet. Tony Guzzi, President and Chief Executive Officer, and Kevin Matz, Executive Vice President – Shared Services, will host the call.

Listeners can access the conference call live over the Internet through a (WEBCAST) link on the Home Page of the Company’s website at http://www.emcorgroup.com at the following times:

Thursday, April 25, 2013

10:30 AM EDT
9:30 AM CDT
8:30 AM MDT
7:30 AM PDT

Please allow 10 minutes prior to the call to visit the site and download and install any necessary audio software. Additionally, investors can access a replay of the webcast through a (REPLAY) link two hours after the call on the home page of the Company’s website. Replay available through May 9th, 2013.

EMCOR Group, Inc. is a Fortune 500® worldwide leader in mechanical and electrical construction services, energy infrastructure and facilities services. This press release and other press releases may be viewed at the Company’s Web site at www.emcorgroup.com.

This release may contain certain forward-looking statements within the meaning of the Private Securities Reform Act of 1995. Any such comments are based upon information available to EMCOR management and its perception thereof, as of this date, and EMCOR assumes no obligation to update any such forward-looking statements. These forward-looking statements may include statements regarding market opportunities, market share growth, gross profit, backlog mix, projects with varying profit margins, and selling, general and administrative expenses. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Accordingly these statements are no guarantee of future performance. Such risk and uncertainties include, but are not limited to, adverse effects of general economic conditions, changes in the political environment, changes in the specific markets for EMCOR‘s services, adverse business conditions, availability of adequate levels of surety bonding, increased competition, unfavorable labor productivity and mix of business. Certain of the risks and factors associated with EMCOR‘s business are also discussed in the Company’s 2012 Form 10-K and in other reports filed from time to time with

From: http://www.dailyfinance.com/2013/04/11/emcor-group-inc-first-quarter-conference-call-to-b/